1.Two cases of intramural pregnancy.
Hyuck Yung KWON ; Ka Yung LEE ; Jun Hee YUN ; Kee Yook LEE ; Ynag Hee PACK ; Byung Un AHN ; Young Cheol BACK ; Sang Kab KIM ; Hwa Sook MOON
Korean Journal of Obstetrics and Gynecology 1993;36(12):3946-3952
No abstract available.
Pregnancy*
2.Alpha-tocopherol Prevents H2O2-induced Tight Junction Occludin Disruption in Blood-Brain Barrier.
Hee Sang LEE ; Kee NAMKOONG ; Ki Hwan YOOK ; Jun Seok AHN ; Maeng Seok NOH ; Dae Jin KIM ; Yoon Hee CHUNG ; Sung Su KIM ; Won Bok LEE ; Kyung Yong KIM
Korean Journal of Physical Anthropology 2006;19(3):223-233
Vitamin E is the most important lipid-soluble antioxidant in humans. Although alpha-tocopherol is suggested that it has protective effect from many diseases, little is known about the prevention of occludin alteration in tight junction of blood-brain barrier (BBB) under pathologic insults producing reactive oxygen species (ROSs). In this study, the effects of alpha-tocopherol on H2O2-induced tight junction occludin were studied. Primary culture of rat brain microvessel endothelial cells was investigated with confocal microscopy, Western blot, and cell viability assay. Alpha-tocopherol had no apparent cytotoxicity up to 2.8 mM. The preincubation with alpha-tocopherol suppressed the H2O2-induced cytotoxicity in Alamar Blue assay and phase contrast microscopy. In confocal laser microscopy and Western blot, H2O2-induced loss of occludin was suppressed by preincubation with alpha-tocopherol. The present findings provide evidence that alpha-tocopherol may be beneficial for cellular protection from pathologic insults. Since alpha-tocopherol was demonstrated to have far fewer adverse effects, it would become a noteworthy nutrient or drug for the treatment of neurodegenerative diseases.
alpha-Tocopherol*
;
Animals
;
Blood-Brain Barrier*
;
Blotting, Western
;
Brain
;
Cell Survival
;
Endothelial Cells
;
Humans
;
Microscopy, Confocal
;
Microscopy, Phase-Contrast
;
Microvessels
;
Neurodegenerative Diseases
;
Occludin*
;
Rats
;
Reactive Oxygen Species
;
Tight Junctions*
;
Vitamin E
;
Vitamins
3.Gastric Neuroendocrine Tumors According to the 2019World Health Organization Grading System: A Single-Center, Retrospective Study
Yuri KIM ; Bokyung AHN ; Kee Don CHOI ; Beom-Su KIM ; Jeong-Hwan YOOK ; Gin Hyug LEE ; Seung-Mo HONG ; Jeong Hoon LEE
Gut and Liver 2023;17(6):863-873
Background/Aims:
Although gastric neuroendocrine tumors (NETs) are uncommon neoplasms, their prevalence is increasing. The clinical importance of the World Health Organization (WHO) classification of gastric NETs, compared with NETs in other organs, has been underestimated.This study aimed to systematically evaluate the clinical and pathologic characteristics of gastric NETs based on the 2019 WHO classification and to assess the survival outcomes of patients from a single-center with a long-term follow-up.
Methods:
The medical records of 427 patients with gastric NETs who underwent endoscopic or surgical resection between January 2000 and March 2020 were retrospectively reviewed. All specimens were reclassified according to the 2019 WHO classification. The clinicopathologic characteristics, treatment, and oncologic outcomes of 139 gastric NETs were analyzed.
Results:
The patients’ median age was 53.0 years (interquartile range [IQR], 46.0 to 63.0 years). The median follow-up period was 36.0 months (IQR, 15.0 to 63.0 months). Of the patients, 92, 44, and 3 had grades 1, 2, and 3 NETs, respectively. The mean tumor size significantly increased as the tumor grade increased (p=0.025). Patients with grades 2 and 3 gastric NETs more frequently had lymphovascular invasion (29.8% vs 10.9%, p=0.005) and deeper tissue invasion (8.5% vs 0%, p=0.012) than those with grade 1 tumors. The overall disease-specific survival rate was 100%. Two patients with grades 2-3 gastric NETs experienced extragastric recurrence.
Conclusions
Although gastric NETs have an excellent prognosis, grade 2 or grade 3 gastric NETs are associated with a larger size, deeper invasion, and extragastric recurrence, which require active treatment.
4.The Role of Aldosterone on the Development of Renal Tubular Reabsorption in Low Birth Weight Infants.
Byung Min CHOI ; Hoe Kyoung KOO ; Jin Won YOOK ; Kyoung Bum KIM ; Gi Young JANG ; Moon Hee KIM ; Kee Hwan YOO ; Young Sook HONG ; Joo Won LEE ; Soon Kyum KIM
Journal of the Korean Pediatric Society 2001;44(11):1233-1242
PURPOSE: To determine the postnatal changes in aldosterone action on the renal tubular reabsorption in low birth weight(LBW) infants, we assessed the relation of the aldosterone concentrations to renal parameters during the first 10 days of life. METHODS: Twenty LBW infants were evaluated and their gestational ages ranged from 32.4 to 39.3 weeks and their birth weights ranged from 1,440 to 2,500 g. Estimated glomerular filtration rate, fractional excretion of sodium(FENa) and potassium(FEK), and plasma aldosterone concentrations were analyzed according to the postnatal age and the conceptional age(CA). RESULTS: Glomerular functions were improved after birth and were correlated with CA. FENa and FEK decreased after birth and correlated with CA. Plasma aldosterone concentrations increased to 318.6 +/- 147.2 ng/dL at 48 hours and then decreased to 162.0 +/- 72.2 ng/dL at 10 days after birth. Plasma aldosterone concentrations of infants less than 38th week of CA were higher than that of infants more than 38th week. There was a significant negative correlation coefficient between plasma aldosterone concentrations and FENa in infants more than 34th week of CA, but not in that of less than 34th week. CONCLUSIONS: LBW infants have higher plasma aldosterone concentrations, but a poor correlation between plasma aldosterone concentration and urinary sodium excretion for the first few days of life and in lower chronologic aged infants. These results show that the renal tubule reabsorption of sodium is less responsive to plasma aldosterone in these infants and, therefore, the careful management of fluid and electrolyte balance is mandatory.
Aldosterone*
;
Birth Weight
;
Gestational Age
;
Glomerular Filtration Rate
;
Humans
;
Infant*
;
Infant, Low Birth Weight*
;
Infant, Newborn
;
Parturition
;
Plasma
;
Sodium
;
Water-Electrolyte Balance
5.Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study.
Min Jeong SONG ; Young Soo PARK ; Ho June SONG ; Se Jeong PARK ; Ji Yong AHN ; Kee Don CHOI ; Gin Hyug LEE ; Hwoon Yong JUNG ; Jeong Hwan YOOK ; Byung Sik KIM
Gut and Liver 2016;10(5):731-738
BACKGROUND/AIMS: Pregnancy-associated gastric cancer is a rare condition. This case-control study was performed to identify the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer. METHODS: All consecutive patients who presented to our tertiary referral hospital with pregnancy-associated gastric cancer from 1991 to 2012 were identified. Two age-, sex-, and stage-matched controls for each case were also identified from the records. Clinicopathological, gynecological, and oncological outcomes were recorded. Immunohistochemical staining was performed for estrogen receptor, progesterone receptor, epidermal growth factor receptor, human epidermal growth factor receptor, and E-cadherin. Fluorescence in situ hybridization was performed for fibroblast growth factor receptor 2. RESULTS: The median overall survival rates of the pregnancy-associated gastric cancer and control groups were 7.0 months and 15.0 months, respectively (p=0.189). Poor prognostic factors included advanced stage and tumor location in the corpus or the entire stomach but not pregnancy status or loss of E-cadherin. Pregnancy-associated gastric cancer was associated with a longer time from diagnosis to treatment (21 days vs 7 days, p=0.021). The two groups did not differ in the expression of the receptors or E-cadherin. CONCLUSIONS: The dismal prognosis of pregnancy-associated gastric cancer may related to the tumor stage and location rather than to pregnancy itself.
Cadherins
;
Case-Control Studies*
;
Diagnosis
;
Estrogens
;
Fluorescence
;
Humans
;
In Situ Hybridization
;
Pregnancy
;
Prognosis*
;
Receptor, Epidermal Growth Factor
;
Receptor, Fibroblast Growth Factor, Type 2
;
Receptors, Progesterone
;
Stomach
;
Stomach Neoplasms*
;
Survival Rate
;
Tertiary Care Centers